This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the Information for Authors.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the Ethical guidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.
Synthesis and Bioactivity of Antitubercular Peptides and Peptidomimetics: an Update

Luis M. De Leon Rodriguez,* Harveen Kaura and Margaret A. Brimble*ab

Mycobacterium tuberculosis is the causative agent of tuberculosis (TB), an infection that has been declared a global public health emergency by the World Health Organization. Current anti-TB therapies are limited in their efficacy and have failed to prevent the spread of TB, due to the long term drug compliance required and the genesis of multidrug-resistant strains (MDR). The number of chemotherapeutic agents currently available to treat MDR is limited, therefore there is a great need for new anti-TB drugs. Anti-TB peptides and peptidomimetics have emerged as an important and growing class of chemotherapeutic agents. This mini-review provides an update on peptides that exhibit very potent anti-TB activity, and their chemical syntheses, which could potentially be included in the pipeline for new anti-TB drug development.

1. Introduction

Mycobacterium tuberculosis (Mtbc) is a Gram-positive pathogen responsible for most cases of tuberculosis (TB), which in 2013 alone resulted in 9 million new cases of TB and 1.5 million deaths.1 Typical medicines used to treat tuberculosis are small organic molecules such as isoniazid, rifampicin, pyrazinamide and ethambutol, which are used as a first-line treatment option. However, if resistance to the first-line anti-TB drugs is observed, then second-line drugs are administered, which include aminoglycosides, d-cycloserine, ethionamide, protonamide, capreomycin (a cyclic pentapeptide), aminosalicylic acid and fluoroquinolones.2 Usually, these drugs are effective if the patient complies with the long treatment period, but lack of compliance can lead to the development of multidrug resistant (MDR) or extremely drug resistant (XDR) Mtbc strains, which are more difficult to treat. Bedaquiline is an anti-TB drug recently approved by the FDA for the treatment of MDR cases where other drugs have failed. However, bacterial resistance and poor patient outcome, has limited the application of bedaquiline as a second-line medication.3,4 Therefore, due to the growing resistance to currently available anti-TB therapeutics, there is a pressing need for the development of new antitubercular agents. In particular, the discovery of molecules that aim for new biomolecular Mtbc targets is important for the future development of drugs to treat MDR and XDR strains. The biomolecular targets inhibited by existing Mtbc drugs and new targets are listed in Table 1 and Table 2 respectively.5 The list is not exhaustive and only intends to illustrate the growing list of targets available to combat persistent Mtbc and its mutants.

Table 1 Biomolecular targets inhibited by existing Mtbc drugs

<table>
<thead>
<tr>
<th>Anti-TB medicine</th>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isoniazid</td>
<td>Enoyl-acyl-carrier protein-reductase</td>
</tr>
<tr>
<td>Rifampicin</td>
<td>DNA dependent RNA polymerase</td>
</tr>
<tr>
<td>Pyrazinamide</td>
<td>Fatty acid synthase</td>
</tr>
<tr>
<td>Ethambutol</td>
<td>Arabinosyltransferase</td>
</tr>
<tr>
<td>Ethionamide</td>
<td>β-ketoacyl ACP synthase</td>
</tr>
<tr>
<td>D-cycloserine</td>
<td>D-alamyl-D-alanine ligase</td>
</tr>
<tr>
<td>Aminoglycosides</td>
<td>Ribosome</td>
</tr>
<tr>
<td>Capreomycin</td>
<td>DNA gyrase</td>
</tr>
<tr>
<td>Fluoroquinolone</td>
<td>ATP synthase (new target)</td>
</tr>
<tr>
<td>Bedaquiline</td>
<td></td>
</tr>
</tbody>
</table>

Table 2 New biomolecular targets for anti-TB drug development.6

<table>
<thead>
<tr>
<th>New Targets</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Naturally occurring peptides and their derivatives are an important and growing class of biopharmaceuticals with a current success rate approximately twice that of small molecule drugs.7 This has been attributed to the advantages of peptides over their small organic counterparts, such as increased target affinity, and fewer off-target side-reactions and thus less side effects.
Fig 1. Structures of potent antitubercular peptides and peptidomimetics.
Table 3. Potent antitubercular peptides and peptidomimetics discussed in this review.

<table>
<thead>
<tr>
<th>Peptide</th>
<th>Source</th>
<th>MIC, µg/mL (strain)</th>
<th>Cytotoxicity</th>
<th>Mechanism/Target</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>HNP-1 (1)</td>
<td>Innate immunity Peptide library</td>
<td>2.5 (H37Rv)</td>
<td>None</td>
<td>Microbial membrane disruption</td>
<td>12</td>
</tr>
<tr>
<td>WKLK2WIK (2) (2013)</td>
<td></td>
<td>1.5 MICo (H37Rv)</td>
<td>Low against macrophage-like human THP-1 cells</td>
<td>Possibly microbial membrane disruption</td>
<td>13</td>
</tr>
<tr>
<td>BB-3497 (3) (2001)</td>
<td>Metalloenzyme inhibitor library</td>
<td>0.25 MICo (H37Rv)</td>
<td>Not determined</td>
<td>Peptide deformylase</td>
<td>15</td>
</tr>
<tr>
<td>1-C13,2,1,2,3,2,1 (4) (2011)</td>
<td>Synthetic</td>
<td>5.3 (BCG)</td>
<td>None against Raw 264.7 and J774 mouse macrophage cell lines</td>
<td>Microbial membrane disruption</td>
<td>16</td>
</tr>
<tr>
<td>capreomycin (5,6) (1960)</td>
<td>Streptomyces CP4</td>
<td>2.0 (H37Rv)</td>
<td>Ototoxic</td>
<td>Ribosome</td>
<td>17</td>
</tr>
<tr>
<td>trichoderin A (7) (2010)</td>
<td>Marine sponge-derived fungus of Trichoderma sp.</td>
<td>0.02 (BCG)</td>
<td>Not determined</td>
<td>ATP synthase</td>
<td>18,19</td>
</tr>
<tr>
<td>trichoderin B (8)</td>
<td>Marine sponge-derived fungus of Trichoderma sp.</td>
<td>0.12 (H37Rv)</td>
<td>Not determined</td>
<td>ATP synthase</td>
<td>18,19</td>
</tr>
<tr>
<td>lariatin A (9) (2006)</td>
<td>Rhodococcus jostii K01-B0171</td>
<td>0.39 (H37Rv)</td>
<td>Not determined</td>
<td>Inhibits cell wall biosynthesis</td>
<td>20</td>
</tr>
<tr>
<td>lassomycin (10) (2014)</td>
<td>Collection of soil actinomycetes</td>
<td>0.78-1.56 (H37Rv)</td>
<td>None against NIH 3T3 and HepG2 cells</td>
<td>ATP-Dependent Protease</td>
<td>21</td>
</tr>
<tr>
<td>ecumin (11) (2014)</td>
<td>Nonomuraea sp. MMS5123</td>
<td>0.26 (H37Rv)</td>
<td>None against VERO cells</td>
<td>ClpC1P1P2</td>
<td>22</td>
</tr>
<tr>
<td>wollamide A (12) (2014)</td>
<td>Streptomyces nov. sp. (MST-115088)</td>
<td>2.11 (BCG)</td>
<td>None against macrophages</td>
<td>Not determined</td>
<td>23</td>
</tr>
<tr>
<td>wollamide B (13)</td>
<td>Marine sponge (Callyspongia aerizusa)</td>
<td>2.29 (BCG)</td>
<td>None against macrophages</td>
<td>Not determined</td>
<td>23</td>
</tr>
<tr>
<td>callyaerin A (14) (2015)</td>
<td>Marine sponge (Callyspongia aerizusa)</td>
<td>2.0 MICo</td>
<td>None against THP-1 and MRC-5 cell lines</td>
<td>Not determined</td>
<td>24</td>
</tr>
<tr>
<td>teixobactin (15) (2015)</td>
<td>β-proteobacterium Eletheria terrae</td>
<td>0.16 (H37Rv)</td>
<td>None against NIH/3T3 mouse embryonic fibroblast</td>
<td>Lipid II and III</td>
<td>25</td>
</tr>
</tbody>
</table>

MICo = minimal inhibitory concentration for 90% bacterial growth inhibition.

However, peptides containing only natural ribosomally synthesised amino acids have some disadvantages, such as poor in vivo stability and oral bioavailability, which limits their potential use as therapeutics. Peptide in vivo instability can be overcome by introducing unnatural amino acids (posttranslationally modified amino acids, D-amino acids, N-alkylated amino acids) or structural constraints (cyclic peptides and cyclic amino acids) into the peptide sequence. However, the design of peptides with favourable oral bioavailability remains challenging. Thus, based on the rich source of naturally occurring peptides and their wide range of biological activities, peptides represent a promising source of potential pharmaceutical agents to treat TB.

Recently, several comprehensive reviews on anti-TB peptides that were derived from natural sources have been reported. However, this review focuses specifically on anti-TB peptides and peptidomimetics that exhibit high potency (Figure 1 and Table 3, 1-15), with a particular emphasis on recently reported anti-TB peptides. In addition, analysis and advances of their chemical syntheses, where available, will also be discussed, with the objective of providing the reader with an insight as to what is involved when trying to generate peptide analogues for development as lead compounds with improved pharmacological properties.

2. Innate Immunity and Synthetic Peptides

The human neutrophil tetradecapeptide 1 (HNP-1, 1) is one of the six human α-defensins which are part of the arsenal of innate immunity to combat infectious microorganisms. The main structural characteristic of α-defensins is a three-stranded β-sheet core stabilized by three intramolecular disulfides (Figure 1). Defensins are active against a broad range of bacteria, fungi, and viruses; they can also act as immunomodulators and are known to neutralize secreted bacterial toxins. It is thought that the bactericidal mechanism of defensins mainly involves microbial membrane disruption.

Previous work has shown that HNP-1 (1) kills Mtb H37Rv in vitro and in vivo by primarily binding to the plasma membrane/cell wall while deoxyribonucleic acid (DNA) appears to be a secondary target.

Importantly and interestingly, low plasma concentrations of HNP-1 (1) have been associated with the genesis of MDR.

The synthesis of HNP-1 (1) and analogues can be accomplished using conventional solid phase peptide synthesis (SPPS) protocols, however, the regiospecific disulfide bond formation is synthetically challenging. Moreover, the disadvantages of using large peptides containing solely natural amino acids for anti-TB treatment, such as HNP-1 (1), are their low plasma stability and high cost of production.
In contrast to HNP-1 (1), a short synthetic nonapeptide, H-WKWLKWKIG-NH₃ (2), was recently reported to exhibit broader antimicrobial activity and more potent anti-TB activity than (1). Nonapeptide (2) was discovered by screening libraries of cationic antimicrobial peptides, which are typically inactive against Mtb due to the resistance conferred by the bacterial envelope, for activity against Mtb. Surprisingly, nonapeptide (2) exhibited a potent MIC₉₀ value of 1.5 μg/mL. The synthesis of nonapeptide (2) was performed using standard Fmoc-SPPS, and due to its short peptide sequence, it is anticipated that large scale production of nonapeptide (2) can be achieved in a cost-efficient manner. However, given the all-ʟ amino acid sequence for nonapeptide (2), it is also anticipated that peptide (2) might exhibit poor in vivo stability and therefore, further peptide modifications might be necessary to develop (2) into a potential lead anti-TB drug candidate.

3. Peptidomimetics

BB-3497 (3) is a peptidomimetic that inhibits peptide deformylase (PDF), an essential bacterial metalloenzyme which deformylates the N-formylmethionine of newly synthesized proteins. Initially, it was shown that BB-3497 (3) displayed moderate bacteriostatic activity against several Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecalis. A few years later, BB-3497 (3) was found to exhibit potent activity against Mtb (MIC 0.25 μg/mL), a level of potency that is similar to front line anti-TB medicines, such as rifampicin and isoniazid. In 2001, prior to the discovery of its anti-TB activity, the asymmetric synthesis of BB-3497 (3) was reported (Scheme 1). The synthesis of 3 was initiated by treating carbonyl-activated acrylic acid 16 with oxazolidinone 17, to provide homochiral acrylate 18. Acrylate 18 then underwent an asymmetric Michael addition reaction with amine 19, to yield the single Michael diastereomer 20. The chiral auxiliary of 20 was then removed under basic conditions, and the resulting amino acid 21 was formulated to give formamide 22. Formamide 22 was then coupled to tert-leucine 23, to give O-benzyl protected dipeptide 24, after which removal of the benzyl protecting group of 24 using catalytic hydrogenation provided the final product 3. Since this initial synthesis of BB-3497 (3), no other synthetic strategies have been reported.

In order to provide further insight into the mechanism of action of BB-3497 (3), several extensive structure activity relationship studies (SAR) have been carried out. A series of BB-3497 analogues where the N-formyl-hydroxylamine metal binding moiety was substituted by N-acetyl hydroxylamine, N-formylamine, hydrazide, amidoxime, N-hydroxurea, thiol, carboxylic acid or phosphorous based chelants were synthesised and evaluated against Escherichia coli PDF.Nickel (PDF.Ni) enzyme and against E. coli (Gram-negative) and Staphylococcus capitis (Gram-positive). BB-3497 and an analogue containing the hydroxamic acid were strong PDF.Ni inhibitors (IC₅₀ = 7 and 1 nM respectively), however, BB-3497 showed the strongest antimicrobial activity. The rest of the analogues were mainly inactive against the enzyme and had no antimicrobial activity. Therefore, it was concluded that the N-formyl-hydroxylamine metal binding moiety was crucial for enzyme inhibition and antibacterial activity. BB-3497 derivatives with a methyl substituted methylene, two and no methylene units between the N-formyl hydroxylamine functionality and the n-butyl side-chain were also inactive against PDF.Ni and had no antimicrobial activity, thus showing that the optimal distance is one unsubstituted methylene unit. In addition, BB-3497 analogues where the n-butyl group was substituted by side-chains such as alkyl, cycloalkyl, benzyll, etc., were prepared. The compounds containing n-butyl (BB-3497) and cyclopentylmethyl groups showed optimal enzyme inhibition and antibacterial activity. Interestingly, although less potent than BB-3497, most derivatives were still active against PDF, but showed a decrease or lack of antimicrobial activity. These differences were attributed to variation in compound lipophilicities. Furthermore, it was revealed that substitutions of the tert-butyl and dimethyl amide moieties were well tolerated, and that these moieties can be investigated further to optimize the physicochemical properties of peptidomimetic 3. Unfortunately, SAR studies of BB-3497 (3) have not been conducted with Mtb.
Peptoids are another class of peptidomimetics where the lateral side-chains are attached to the nitrogen atom of the amide bond instead of the α-carbon. This feature gives peptoids increased proteolytic stability. A potent anti-TB 4-mer peptoid, named 1-C13₄mer (4) has been reported in the literature. This peptoid is composed of two N-lysine residues (N-(4-aminobutyl)glycine), two (S)-N-(1-phenylmethyl) glycine units and a N-(tridecyl)glycine residue at the N-terminus. This composition gives 1-C13₄mer (4) surfactant-like character that could presumably direct its activity towards Mtb membrane disruption. The synthesis of 4 was easily accomplished by the submonomer solid phase method, which consists of consecutive attachment of bromoacetic acid via DIC activation onto the solid support, followed by nucleophilic substitution of the corresponding side-chain-containing amino moiety (Scheme 2).

### 4. Peptides from Natural Sources

#### 4.1 Capreomycin

Capreomycin is one of the few antitubercular peptide medicines that is currently used to treat cases of MDR TB. A family of four capreomycin peptides was first discovered in 1960, and both capreomycin IA (5) and IB (6) have been co-administered intramuscularly to treat cases of MDR TB for over 25 years. However, capreomycin usage is limited due to its renal and auditory toxicities. The capreomycins contain two diaminopropanoic acid residues, the α,β-unsaturated amino acid ureido-dehydroalanine and the cyclic guanidino amino acid (2S,3R)-capreomycinidine. Several early reports on the synthesis of capreomycin are found in the literature, however, most of these syntheses are low yielding, which is attributed to the difficult stereospecific preparation of the key component capreomycinidine. Therefore, capreomycin is commercially prepared by biosynthesis.

One of the most recent successful chemical syntheses of capreomycinidine and capreomycin IB (6) was reported in 2003. In this account, the synthesis of capreomycinidine was initiated by the enolate-aldimine reaction between chiral glycinate 25 and benzyl imine 26 (Scheme 3), which yielded the Mannich product 27 as a mixture of diastereomers, (3.3:1; (2S,3R):(2S,3S)) that were epimeric at the α-carbon. Guanidylation of 27 with isothiourea 28 only took place with the major diastereomer (2S,3R), to give 29 in 74% yield. Removal of the tert-butyldimethylsilyl protecting group generated alcohol 30, which was followed by an intramolecular Mitsunobu cyclization reaction to yield compound 31. Final protecting group removal gave (2S,3R)-capreomycinidine (32) in a 20% overall yield.
With the capreomycidine building block in hand, capreomycin IB (6) was then synthesized using solution phase methods (Scheme 4). Terminally protected diaminopropanoic acid 33 was coupled with lysine 34, followed by hydrolysis of the methyl ester to give dipeptide 35. Coupling of 35 with R-α-formylglycine diethylacetal ethyl ester 36 provided tripeptide 37 as a diastereomeric mixture (2.6:1 of R:S epimers). Tripeptide 37 was then coupled to dipeptide 38 to give pentapeptide 39 in 87% yield. Chemoslective Hofmann rearrangement facilitated the direct conversion of the primary amide of the asparagine residue in 39 into the primary amine in 40. Coupling of 40 with a protected (2S,3R)-capreomycidine (41) gave hexapeptide 42. After CBz removal and ethyl ester hydrolysis of hexapeptide 42, intramolecular cyclisation using EDCI provided the cyclic peptide 43 in a low 20% yield. Interestingly, only the desired diastereomer was obtained after macrocyclization indicating that its linear precursor cyclizes more efficiently than the undesired diastereomer. Lastly, the Boc protecting group of 43 was removed and the acetal moiety was cleaved with acid, followed by reaction of the corresponding aldehyde intermediate with urea, to give capreomycin IB (6).

4.2 Trichoderins
Trichoderins (7-8) are peptaibols (peptides containing \( \alpha \)-aminoisobutyric acid (Aib) and a C-terminal alcohol) which have shown to be very potent against dormant and live \( \text{Mtbb} \) bacilli.\(^{18}\) This anti-TB activity of trichoderins has been assigned to the inhibition of bacterial ATP synthase.\(^{19}\) Trichoderins contain the unnatural amino acid 2-amino-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD) and a (2\( R \))-methyl octyl chain at the N-terminus. The synthesis of trichoderins is complex due to the presence of AHMOD, the C-terminal alcohol moiety and consecutive sterically hindered Aib residues. Synthetic protocols to prepare AHMOD can be found in the literature,\(^{38}\) but most are lengthy, low yielding and difficult to scale up. However, an improved synthesis of a stereoisomer of this uncommon amino acid was recently reported (Scheme 5).\(^{39}\)

This synthesis began with the stereoselective methylation of \( N\)-Boc glutamic acid dimethyl ester 44, to afford compound 45, which is regioselectively reduced to aldehyde 46. Conversion of 46 to the desired homologated aldehyde 49 proceeded via a Wittig reaction with the ylide of 47 via alkene 48 which was further hydrolysed to 49 under acidic conditions. The aldol reaction of 49 with the enolate of 2-butanone (50) gave the desired aldol products 51, as an inseparable 1:1 mixture of C6 epimers. Removal of the Boc protecting group under conventional acidic conditions followed by protection of the crude amine with an Fmoc protecting group, facilitated the chromatographic separation of the desired diastereomer 52 in a low overall 24% yield. The final methyl ester hydrolysis of 52 to give AHMOD 53, proceeded in excellent yield (98%) under basic conditions that maintained the integrity of the Fmoc protecting group and the \( \beta \)-hydroxyketone moiety.

To the best of our knowledge the total synthesis of the trichoderins 7-8 has not been reported to date, but the preparation of the closely related compound culicinin D (54) has been accomplished via solid phase peptide synthesis (Figure 2).\(^{38,40}\) During the synthesis of culicinin D (54), two problematic steps were encountered; these were the attachment of the alcohol unit to the solid support, and the difficult couplings of the consecutive Aib residues. These problems were minimized by attaching the amino group of the aminoalcohol building block to the resin instead of the alcohol, which then undergoes an intramolecular \( O-N \) acyl shift upon peptide synthesis completion, and by coupling the Aib residues with the powerful coupling agent fluoro-\( N,N,N',N' \)-tetramethylformamidinium hexafluorophosphate.\(^{40}\) However, the reported final overall yield of culicinin D is still low (6%), and further work is required in order to access larger amounts of this compound. Due to the structural similarity of trichoderins 7-8 and culicinin D (54), it is anticipated that similar challenges will be encountered during the synthesis of the trichoderins.

4.3 Lasso Peptides

Lariatin A (9) is a lasso peptide, in which the C-terminal segment (Trp9-Pro18) passes through the ring structure formed by the N-terminal segment (Gly1-Glu8) (see insert figure in the structure of 9 in Fig 1).\(^{41}\) Lariatin A (9) was selective against mycobacteria with strong activity against \( \text{Mtbb} \). It is believed that Lariatin A (9) inhibits cell wall biosynthesis,\(^{20}\) however, this mechanism of action has not been validated. Lassomycin (10) is another newly discovered lasso peptide, which showed potent activity (MIC 0.8–3 \( \mu \)g/mL), against a variety of \( \text{Mtbb} \) isolates, including MDR and XDR isolates.\(^{21}\) It has been reported that lassomycin kills \( \text{Mtbb} \) by targeting ATP-dependent protease ClpC1P1P2.\(^{21}\)
To date, the chemical synthesis of lasso peptides has not been reported, but their biosynthesis is well understood, thus allowing the engineering of novel structures.\(^{34}\) Biosynthetically, lasso peptides are ribosomally synthesized and posttranslationally modified, and this process requires at least three genes which encode for a precursor peptide, a cysteine protease, and an ATP-dependent lactam synthetase (Figure 3). The precursor peptide is composed of an N-terminal leader peptide, which is fused to the core and tail of the lasso peptide sequence. It is hypothesised that the leader peptide acts as a chaperone to mediate pre-folding during maturation, because the threading cannot occur after ring formation. Thus, once the precursor peptide is folded, the N-terminal leader peptide is cleaved, and macro lactamization of the activated peptide generates the mature peptide with a lasso topology.\(^{42}\)

4.4 Cyclic Peptides

Finally, the largest class of peptides with anti-TB activity are cyclic peptides. Ecumicin (11) is a newly discovered cyclotetradepsipeptide which has shown potent anti-TB activity against Mtb H37Rv and streptomycin, rifampicin and cycloserine resistant Mtb strains.\(^{43}\) Ecumicin contains several unnatural amino acids in its sequence, all of which are commercially available or can be prepared from commercially available building blocks. For example N-methyl-4-methoxytryptophan can be synthesised from the readily available 4-methoxytryptophan using well known N-methylation techniques.\(^{44}\) Although the chemical synthesis of ecumicin (11) has not been reported, it is anticipated that its synthesis can be accomplished based on previous reports of structurally similar compounds. Recently, the bactericidal mode of action of ecumicin (11) was attributed to decoupling of ClpC1-mediated ATP hydrolysis from ClpP1P2 proteolysis. ClpC1 is an Mtb essential hexameric ATPase, which associates and supports ATP-dependent protein degradation by ClpP, a compartmentalized protease complex found in many bacteria, mitochondria, and chloroplasts. The function of ClpC1 is to bind certain cell proteins and to unfold and translocate them into ClpP for degradation.\(^{22}\) Thus, by inhibiting the action of ClpC1, ecumicin (11) stimulates ATPase activity.

The wollamides 12-13 are cyclohexapeptides containing the non-natural amino acids D-ornithine (D-Orn), D-Leu, or allo-Ile. These peptides were active against M. bovis, BCG, but their activity against Mtb has not been reported.\(^{23}\) Moreover, the simple structure of these wollamides when compared to other peptides described herein, suggests them to be potential drug lead candidates for future development of anti-TB agents. Callyaerin A (14) is a naturally occurring cyclic peptide derived from the marine sponge Calysspongia aezus, for which the cyclic link occurs between the N-terminus and the side-chain of an α,β-dehydroamino acid,\(^{45}\) namely (Z)-2,3-diaminoacrylic acid.\(^{24}\) Callyaerin A (14) exhibited potent activity against Mtb with no observed cytotoxicity. It is anticipated that both the endoligamino group and proline residues in the cyclic ring provides rigidity to the system, which might promote its bioactivity, whilst the hydrophobic residues in the linear chain might contribute to the bactericidal specificity of the peptide.\(^{24}\) The chemical synthesis of the callyaerins has not
producing teixobactin is the synthesis of its total chemical synthesis. The biggest challenge to be either active against Mtb (MIC 0.16 µg/mL), and unlike any known anti-TB agents, it inhibits the synthesis of important bacterial cell wall components, namely peptidoglycan and teichoic acid, by binding to their precursors, lipid II and III respectively.25 The main target of teixobactin is lipid II (teixobactin binds to lipid II in a 2:1 ratio). Lipid II is a glycopeptide that stabilizes the exterior cell wall via saccharide polymerization and peptide side-chain cross-linking. This unique mechanism of action is believed to minimize the development of resistance, which makes teixobactin a promising lead for Mtb drug development.

Teixobactin (15) is an undecapeptide which comprises a cyclotetradepsipeptide containing the unnatural amino acid enduracididine. Teixobactin exhibits potent activity against Mtb (MIC 0.16 µg/mL), and unlike any known anti-TB agents, it inhibits the synthesis of important bacterial cell wall components, namely peptidoglycan and teichoic acid, by binding to their precursors, lipid II and III respectively.25 The main target of teixobactin is lipid II (teixobactin binds to lipid II in a 2:1 ratio). Lipid II is a glycopeptide that stabilizes the exterior cell wall via saccharide polymerization and peptide side-chain cross-linking. This unique mechanism of action is believed to minimize the development of resistance, which makes teixobactin a promising lead for Mtb drug development.

To improve the potency and to gain further understanding of the biological properties of teixobactin (15), it is crucial to execute its total chemical synthesis. The biggest challenge to producing teixobactin is the synthesis of l-allo-enduracididine (56) (Scheme 7), an amino acid which is biochemically synthesized from arginine.48 Some reports on the synthesis of 56 or analogues can be found in the literature but they either proceed with poor stereoselectivity or are difficult to scale up.49,50 Recently, an improved (stereoselective-scalable) synthetic protocol of 56 was reported (Scheme 7).51 The synthesis commenced with the protection of the carboxylate group of the N-Boc protected trans-hydroxyproline (57) to give tert-butyl ester 58. This ester was treated with methanesulfonyl chloride and base to generate the corresponding mesylate which was substituted by an azido group to generate azidoproline 59. Compound 59 was then oxidized to lactam 60. Reductive ring opening of 60 was accomplished with NaBH₄ in a mixture of ethanol-buffer pH = 7 to yield 61. In this step, the presence of the sterically hindered tert-butyl protecting group was advantageous, since it helped to inhibit lactone formation during the ring opening reaction. The azide of 61 was then reduced by Pd catalyzed hydrogenation to give the amino compound 62, which was then smoothly guanidinylated to give 63 in excellent 98% yield. The key ring closure step was accomplished by nucleasephilic substitution of the protected guanidine to the mesylated hydroxyl group of 63, which generated 64. Final protecting group removal gave enduracididine 56 in 30% overall yield.

With a range of synthetic strategies available for the preparation of enduracididine (56), it is anticipated that the synthesis of teixobactin can be accomplished using conventional SPPS. In addition, it is recommended that the cyclic tetradepsipeptide core of teixobactin (15) be constructed via macrolactamization rather than macrolactonization.52

5. Conclusions

In conclusion, there has been a significant increase in the number of peptides extracted from natural sources which have shown potent inhibitory activity against new Mtb biotargets, therefore they are considered to be important lead compounds for the development of new drugs to treat MDR and XDR cases of Mtb. However, most of these peptides contain complex unnatural amino acids and motifs, which as highlighted in this review, are chemically difficult to synthesise in a robust and efficient manner. Chemists around the globe have engaged in solving these problems in order to provide sufficient quantities of newly discovered anti-TB peptides or analogues with improved activity, in an effort to develop new drugs to fight the growing TB pandemic. Furthermore, structurally simpler peptides and peptidomimetics have also
emerged as promising lead compounds that can potentially be developed into new anti-TB drug candidates.

Acknowledgements

The graphical abstract Image is adapted from a micrograph of Mycobacterium tuberculosis. Image courtesy of Dr Ray Butler and Janice Carr (Centres for Disease Control).

References